Date: 2013-07-30
Type of information: Licensing agreement
Compound: POTELLIGENT® CHOK1SV Cell Line
Company: BioWa (Japan) Lonza (Switzerland) Pfizer (USA - NY)
Therapeutic area:
Type agreement: licensing
Action mechanism: POTELLIGENT® CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines the power of BioWa’s engineered glycosylation POTELLIGENT® Technology with the advantages of Lonza’s proprietary GS Gene Expression System™, which includes the industry-leading CHOK1SV cell line.
Disease:
Details: * On July 30, 2013, BioWa and Lonza have announced that they have entered into research agreements with Pfizer allowing the use of the POTELLIGENT®CHOK1SV Cell Line in the research and development of multiple proprietary antibodies in Pfizer’s pipeline.
Financial terms:
Latest news:
